TMC Group Reports Progress on Capacity Expansion Ahead of EANM 2026
Vancouver, British Columbia--(Newsfile Corp. - October 8, 2026) - Earlier this year, TMC Group, a Canadian manufacturer of enriched stable isotopes, announced plans to increase production capacity by 50 percent. Today, the company is commissioning new production lines that are already producing material, marking an early milestone in that work. The company will be exhibiting at the European Association of Nuclear Medicine (EANM) Annual Congress in Vienna next week, where the team will c
Technology, Biotechnology, Chemical, Pharmaceuticals
2026-10-08 12:00 PM EDT | TMC Group
Enoumena Therapeutics and AOP Health Announce Exclusive Canadian Commercialization Agreement for SIBBORAN(R) (landiolol)
Quebec and Vienna, Austria--(Newsfile Corp. - October 8, 2026) - Enoumena Therapeutics Inc. and AOP Health today announced an exclusive commercialization agreement to expand Canadian institutional access to PrSIBBORAN® (landiolol hydrochloride), an ultra-short-acting, selective beta-1 adrenergic receptor blocker. Authorized by Health Canada in 2023, SIBBORAN is indicated for the short-term reduction of ventricular rate in patients with supraventricular tachycar
Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-10-08 10:47 AM EDT | Enoumena Therapeutics Inc.
Enoumena Therapeutics et AOP Health annoncent une entente exclusive de commercialisation au Canada de SIBBORAN(R) (landiolol)
Québec et Vienne, Autriche--(Newsfile Corp. - 8 octobre 2026) - Enoumena Therapeutics Inc. et AOP Health ont annoncé aujourd'hui la conclusion d'une entente exclusive de commercialisation visant à élargir l'accès des établissements de santé canadiens à PrSIBBORAN® (chlorhydrate de landiolol), un bêtabloquant sélectif des récepteurs bêta-1 adrénergiques à action ultra-courte. Autorisé par Sant
Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-10-08 10:47 AM EDT | Enoumena Therapeutics Inc.
Simple Eye Test and Glasses Could Help Double a Child's Lifetime Earnings in Both the USA and Canada
New IAPB finding shows a child's lifetime earnings could double in total of 23 countries worldwide if vision problems are identified and corrected early "A simple eye test and glasses could be one of the best investments a parent can make" IAPB CEO Finding published on World Sight Day, as governments urged to ensure every child has access to sight tests and glasses
Education, Healthcare and Hospitals, Pharmaceuticals
2026-10-08 9:00 AM EDT | International Agency for the Prevention of Blindness
Tate & Lyle and Bioharvest Reach Key Milestone in Next-Generation Sweetener Development Programme
British Columbia and Rehovot, Israel--(Newsfile Corp. - October 8, 2026) - Tate & Lyle PLC (Tate & Lyle), a global leader in ingredient solutions for healthier food and beverages, and BioHarvest Sciences Inc. (NASDAQ: BHST) (TASE: BHST) (BioHarvest), today announced an important milestone in their next-generation sweetener development programme. The programme has demonstrated that BioHarvest's Botanical Synthesis™ platform is capable of producing the targeted ne
Biotechnology, Pharmaceuticals, Health
2026-10-08 8:00 AM EDT | BioHarvest Sciences Inc.
TempraMed Granted Mexican Patent for Newest Product, VIVI Box
Highlights Covers core innovations underpinning TempraMed's VIVI Box™ multi-medication storage platform Strengthens the Company's intellectual property position in one of the world's largest healthcare and consumer markets Supports commercialization strategy and strategic engagement with appliance manufacturers across America's premium refrigeration sector Patent term extends through Octobe
Technology, Biotechnology, Pharmaceuticals, Health
2026-10-08 3:05 AM EDT | TempraMed Technologies Ltd.
Hemostemix Announces Full LARTA Approval, Manufacturing Progress and Financing Update
Calgary, Alberta--(Newsfile Corp. - October 7, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") announces that it has received full approval from the National Longevity and Regenerative Therapy Board of The Bahamas (LARTA Board), including ethics approval from the LARTA Ethics Committee, for its commercial Phase 1 study of VesCell™as a treatment for angina, vascular dementia and pain. This milestone advances the Company's clinical developmen
Biotechnology, Pharmaceuticals, Health
2026-10-07 2:37 PM EDT | Hemostemix Inc.
PharmaTher Launches M3DICINES(TM) National Network Program to Provide 3D-Printed Medicines for Rare Diseases, Discontinued Medicines, Drug Shortages and National Emergencies
Toronto, Ontario--(Newsfile Corp. - October 7, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) (the "Company" or "PharmaTher"), a specialty pharmaceutical company advancing 3D-printed medicines, today announced the launch of the M3DICINES™ National Network Program (the "Network Program"). The program will build a national network of qualified sites that make personalized medicines on CraftMake™ pharmaceutical 3D printers, supported by PharmaTher's M3DICINES&#
Biotechnology, Pharmaceuticals
2026-10-07 8:00 AM EDT | PharmaTher Holdings Ltd.
Palindrome Pharma Launches in Canada to Unlock Access to High-Quality Biosimilar Medicines
Toronto, Ontario--(Newsfile Corp. - October 7, 2026) - Palindrome Pharma, a new pharmaceutical company focused on biosimilar medicines, today announced its launch in Canada, with a mission to broaden access to high-quality biologic therapies and contribute to a more sustainable Canadian healthcare system. As demand for biologic medicines continues to grow, biosimilars have an important role to play in creating greater choices for Canadians. Palindrome Pharma will work with global and C
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-10-07 12:30 AM EDT | Palindrome Pharma Inc.
Unbuzzd Wellness Inc. Announces Refiling of Amended and Restated Interim Financial Statements and MD&A
Vancouver, British Columbia--(Newsfile Corp. - October 6, 2026) - Unbuzzd Wellness Inc. (the "Company" or "Unbuzzd"), the company behind unbuzzd, announces that it has filed amended and restated unaudited condensed interim consolidated financial statements for the three and nine months ended April 30, 2026 and 2025 (the "Amended Financial Statements"), together with amended and restated management's discussion and analysis (the "Amended MD&A"). The
2026-10-06 9:57 PM EDT | Unbuzzd Wellness Inc.
Okogen Receives CDSCO Authorization to Advance the EMERALD Phase 1/2 Study of Treyegen (OKG-0303) for Acute Infectious Conjunctivitis
Plano, Texas--(Newsfile Corp. - October 6, 2026) - Okogen, Inc., a clinical-stage biotechnology company focused on developing innovative therapies for infectious diseases, today announced that the Central Drugs Standard Control Organisation (CDSCO), India's national drug regulatory authority, has authorized the EMERALD study, the Company's Phase 1/2 clinical trial evaluating Treyegen (OKG-0303) for the treatment of acute infectious conjunctivitis. To view the f
Biotechnology, Pharmaceuticals
2026-10-06 9:28 AM EDT | Okogen
Telescope Innovations to Attend the 2026 Cantech Investment Conference in Toronto
Vancouver, British Columbia--(Newsfile Corp. - October 6, 2026) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) ("Telescope" or the "Company"), a leading developer of Physical AI systems, including Self-Driving Laboratories ("SDLs"), and enabling technologies and services for the global pharmaceutical and high-value chemical industries, today announced that members of its leadership team will be in Toronto on October 7 and 8, 2026, including attendance at the Can
Technology, Chemical, Pharmaceuticals
2026-10-06 8:00 AM EDT | Telescope Innovations Corp.
Phio Pharmaceuticals to Present at The Global Markets Virtual Forum October 8, 2026
King of Prussia, Pennsylvania--(Newsfile Corp. - October 6, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing cancer therapeutics based on its proprietary INTASYL® siRNA gene-silencing platform, today announced that Robert Bi
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-10-06 7:00 AM EDT | Phio Pharmaceuticals Corp.
Telescope Innovations Reports 60% Revenue Growth in Preliminary Unaudited Fiscal Year 2026 Results
Vancouver, British Columbia--(Newsfile Corp. - October 5, 2026) - Telescope Innovations Corp. (CSE: TELI), (OTCQB: TELIF), (FSE: J4U), ("Telescope" or the "Company"), a leading developer of Physical AI systems, including Self-Driving Laboratories ("SDL"), enabling technologies, and services for the global pharmaceutical and chemical industries, today reported 60% growth in gross revenue for fiscal 2026, with revenue reaching C$9.3 million, compared with C$5.8 million in f
Technology, Chemical, Pharmaceuticals
2026-10-05 8:00 AM EDT | Telescope Innovations Corp.
Extendicare Announces Timing of 2026 Third Quarter Results and Conference Call
Markham, Ontario--(Newsfile Corp. - October 5, 2026) - Extendicare Inc. (TSX: EXE) ("Extendicare" or the "Company") announced today that it plans to release its financial results for the third quarter of 2026 after market close on Thursday, November 5, 2026. A conference call hosted by Michael Guerriere, President and Chief Executive Officer and David Bacon, Executive Vice President and Chief Financial Officer, will be held on Friday, November 6, 2026, at 11:30 a.m. (EST) to discuss the
Healthcare and Hospitals, Pharmaceuticals, Health
2026-10-05 8:00 AM EDT | Extendicare Inc.
PharmaTher Outlines Corporate Strategy and Upcoming Milestones; Launches New Corporate Website and Rebrands PERSONALIZ3D as M3DICINES
Highlights M3DICINES™ 3D-printed medicines platform. One platform for PharmaTher's proprietary products, its network of CraftMake™ placements and partner services: CDMO, white-label products, formulation licensing and clinical trial supply. Commercial launch of M3DICINES™. Initial orders of the CraftMake™ pharmaceutical 3D printer, the platform's entry point, are planned for Q4 2026.
Biotechnology, Pharmaceuticals
2026-10-05 8:00 AM EDT | PharmaTher Holdings Ltd.
Phio Pharmaceuticals to Present at the National Investment Banking Association (NIBA) 153rd Conference
King of Prussia, Pennsylvania--(Newsfile Corp. - October 5, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing cancer therapeutics based on its proprietary INTASYL® siRNA gene-silencing platform, today announced that it has accepted the invitation to present at the National Investment Banking Association's (NIBA) 153rd Conference on October 6-7, 2026, in Fort Lauderdale, Florida. Robert Bitterman, President and Chief Executive Offic
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-10-05 7:00 AM EDT | Phio Pharmaceuticals Corp.
TempraMed Announces VIVI Cap Smart Connectivity with Apple Health and Google Fit, Providing Better Health Outcomes and Data Tracking
Toronto, Ontario--(Newsfile Corp. - October 5, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (OTCQB: TMPTF) (FSE: 9DY) ("TempraMed" or the "Company"), a medical technology company transforming the storage, protection and management of temperature-sensitive medications, is pleased to announce that its VIVI Cap Smart™ platform now supports connectivity with Apple Health and Google Fit, advancing the Company's strategy to make injectable medication use visible within leading health and w
Technology, Biotechnology, Pharmaceuticals, Health
2026-10-05 3:05 AM EDT | TempraMed Technologies Ltd.
Voyageur Pharmaceuticals Announces Completion of Shares for Debt Settlement
Calgary, Alberta--(Newsfile Corp. - October 2, 2026) - Voyageur Pharmaceuticals Ltd. (TSXV: VM) (OTC Pink: VYYRF) ("Voyageur" or the "Company"), a Canadian developer of pharmaceutical-grade barium and iodine contrast media for medical imaging, is pleased to announce that, further to the Company's news release dated September 24, 2026, the Company has completed its previously announced shares for debt settlement, in settlement of outstanding indebtedness in the aggregate amount o
Pharmaceuticals, Mining and Metals
2026-10-02 4:29 PM EDT | Voyageur Pharmaceuticals Ltd.
PharmaTher Enters into Exclusive North American Distribution Agreement with Craft Health for CraftMake(TM) Pharmaceutical 3D Printing Platform
Highlights PharmaTher is now the exclusive distributor in North America of Craft Health's CraftMake™ 3D printers, CraftControl™ software, CraftBlends™ printable formulations, consumables, and service. Exclusivity covers every key customer segment: compounding pharmacies (503A and 503B), telehealth and digital health companies, CDMOs, hospitals, academic, research, and government institutions, and pharmaceutic
Biotechnology, Pharmaceuticals
2026-10-01 8:00 AM EDT | PharmaTher Holdings Ltd.